Home › Funds › VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. › DGX

VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. position in DGX

QUEST DIAGNOSTICS INC · Health Care

VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. reported holding 193,776 shares of DGX (QUEST DIAGNOSTICS INC) in its Q3 2026 13F filing — a position valued at US$45.2M, representing 0.34% of its reported portfolio and ranking #45 among its reported holdings. VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. has disclosed DGX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)193.78K sh
Reported value held$45.16M
Portfolio Weight0.34%
First reportedQ2 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.'s DGX position evolved

VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. first disclosed a stake in DGX in Q2 2024 at 356,390 shares (US$48.8M). The position peaked in Q4 2024 at 514,558 shares, worth US$77.6M. Across 10 filings, VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 193,776 shares valued at US$45.2M — a reduction of -49,131 shares quarter over quarter.. Notable position changes include a 31% increase in Q4 2024 (shares rose 12% over the following quarter), a 49% trim in Q4 2025 (shares rose 13% over the following quarter), a 46% increase in Q1 2026 (shares rose 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 356.39K $48.78M New
Q3 2024 393.02K $61.02M Add
Q4 2024 514.56K $77.63M Add
Q1 2025 431.30K $72.98M Reduce
Q2 2025 408.20K $73.32M Reduce
Q3 2025 341.65K $65.11M Reduce
Q4 2025 175.15K $30.39M Reduce
Q1 2026 256.30K $50.23M Add
Q2 2026 242.91K $51.48M Reduce
Q3 2026 193.78K $45.16M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DGX and 13F data

DGX (QUEST DIAGNOSTICS INC) is a Health Care company. 26 other funds we track also report a position in DGX — the largest reported positions include Boston Partners (US$1.08B), EdgePoint Investment Group Inc. (US$476.4M), Grantham, Mayo, Van Otterloo & Co. LLC (US$449.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DGX

All DGX fund holders →

FAQ

How long has VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. held DGX?

VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. has disclosed DGX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.'s current position in DGX?

As of Q3 2026, VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. holds 193.78K shares of DGX (QUEST DIAGNOSTICS INC), valued at $45.16M, representing 0.34% of its reported portfolio and ranking #45.

Has VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. been buying or selling DGX?

In the latest 13F filing (Q3 2026), VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. reduced its position in DGX. The position peaked in Q4 2024 at 514.56K shares.

Which other funds hold DGX?

Other major institutional holders of DGX include Boston Partners, EdgePoint Investment Group Inc., Grantham, Mayo, Van Otterloo & Co. LLC, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.